---
title: "ADICON Delays Shareholder Circular as Crown Bioscience Deal Awaits Regulatory Approvals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286253929.md"
description: "ADICON Holdings Limited has delayed sending its shareholder circular regarding the acquisition of Crown Bioscience International due to pending regulatory approvals and shareholder consent. Originally expected by April 30, 2026, the timeline will be revised as the company works with advisers to secure necessary consents. The acquisition's completion remains uncertain, impacting shareholders and potential investors. The latest analyst rating for ADICON stock (HK:9860) is a Buy with a price target of HK$7.00."
datetime: "2026-05-13T11:22:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286253929.md)
  - [en](https://longbridge.com/en/news/286253929.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286253929.md)
---

# ADICON Delays Shareholder Circular as Crown Bioscience Deal Awaits Regulatory Approvals

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from ADICON Holdings Limited ( (HK:9860) ) is now available.

ADICON Holdings Limited has provided an update on its proposed acquisition of 100% of the shares of Crown Bioscience International, noting that completion remains subject to several conditions precedent. These include multiple regulatory approvals and shareholder approval, and the company is working with professional advisers and authorities to secure the remaining consents.

Because key regulatory approvals are still pending, ADICON will delay sending the shareholder circular that was originally expected by April 30, 2026, and will announce a revised timeline in due course. The company cautioned that the acquisition may or may not proceed, underscoring ongoing uncertainty for shareholders and potential investors around the timing and likelihood of this major transaction closing.

The most recent analyst rating on (HK:9860) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on ADICON Holdings Limited stock, see the HK:9860 Stock Forecast page.

**More about ADICON Holdings Limited**

ADICON Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the healthcare and diagnostic services sector. The company focuses on expanding its capabilities and market reach through strategic acquisitions, positioning itself to broaden its service offerings and strengthen its competitive standing in regional and international markets.

**Average Trading Volume:** 1,089,624

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$2.92B

Find detailed analytics on 9860 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [09860.HK](https://longbridge.com/en/quote/09860.HK.md)

## Related News & Research

- [VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News](https://longbridge.com/en/news/286964504.md)
- [Crown Crafts Announces Quarterly Cash Dividend | CRWS Stock News](https://longbridge.com/en/news/286405291.md)
- [Massive Bio and Just Worldwide to expand cancer trial access](https://longbridge.com/en/news/286630945.md)
- [Orca Bio Appoints Bijan Nejadnik, M.D., as Chief Medical Officer](https://longbridge.com/en/news/286765565.md)
- [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md)